13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q4 2023 · Filed November 13, 2023 · Accession 0001910264-23-000007
Total Value
$195.1M
Positions
6
Other Managers
0
Confidential Omitted
No
Holdings (6)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | ARCELLX INC. | ACLX | 3,946,630 | $141.6M | 72.57% |
| 2 | MINERALYS THERAPEUTICS | MLYS | 1,794,600 | $17.1M | 8.75% |
| 3 | DESIGN THERAPEUTICS INC | DSGN | 6,526,476 | $15.4M | 7.89% |
| 4 | ARS PHARMACEUTICALS | SPRY | 4,012,903 | $15.2M | 7.77% |
| 5 | EFFECTOR THERAPEUTICS INC | 28202V108 | 6,822,114 | $4.0M | 2.06% |
| 6 | NKARTA INC. | NKTX | 1,333,333 | $1.9M | 0.95% |